KRAS multi-inhibitor
KRAS multi-inhibitor
Search
Oxidase Inhibitor
Oxidase Inhibitor
Immunomodulator
Immunomodulator
SGLT2 inhibitor
BI 765845: Heart disease modulator | Myocardial infarction
BI 765845: Heart disease modulator | Myocardial infarction
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
WW Contacts Human Pharma OCTOBER 2024 CORP_4.pdf
BI 1291583: CatC Inhibitor
BI 1291583: CatC Inhibitor
Phospholipid modulator
Phospholipid modulator
Vascular modulator
Vascular modulator
Ion channel inhibitor
Immunomodulator
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
KRAS multi-inhibitor
Phospholipid modulator
Partnering in Mental Health Disorders HP OCTOBER 2024 CORP.pdf
Vascular modulator
Partnering in Cardio-Renal-Metabolic HP OCTOBER 2024 CORP.pdf
Partnering with Boehringer Ingelheim HP OCTOBER 2024 CORP.pdf
Partnering in Immunology & Resp HP OCTOBER 2024 CORP.pdf
October 2024 Pipeline
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Lysophospholipase inhibitor
Test Teaser Card Download to show up at the end of an article
Test
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares